|
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Single Nucleotide Polymorphisms (SNPs) of P53 Pro72Arg, MDM2 SNP309, P21 Ser31Arg, ER SNP594, HER2 Ile655Val, and FGFR2 rs2981582 have drawn attention as genetic factors associated with cancer risk.
|
31759353 |
2019 |
|
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The <i>TP53</i> Arg72Pro (rs1042522 C>G) polymorphism has been reported to be associated with the risk of several types of adult cancers; however, its risk for pediatric cancers remains unclear.
|
31293648 |
2019 |
|
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
TP53 Arg72Pro (rs1042522 C > G) and miR-34b/c rs4938723 (T > C) polymorphisms have been known to modify cancer susceptibility.
|
31325764 |
2019 |
|
rs1131691014
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Single Nucleotide Polymorphisms (SNPs) of P53 Pro72Arg, MDM2 SNP309, P21 Ser31Arg, ER SNP594, HER2 Ile655Val, and FGFR2 rs2981582 have drawn attention as genetic factors associated with cancer risk.
|
31759353 |
2019 |
|
rs1131691014
|
|
|
0.100 |
GeneticVariation |
BEFREE |
TP53 Arg72Pro (rs1042522 C > G) and miR-34b/c rs4938723 (T > C) polymorphisms have been known to modify cancer susceptibility.
|
31325764 |
2019 |
|
rs28934576
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The presence of R273H-P53 conferred the cancer cells with drug resistance not only against the widely used chemotherapeutic agents like cisplatin (CDDP) or 5-flurouracil (5-FU) but also against potent alternative modes of therapy like proteasomal inhibition.
|
30723502 |
2019 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Single Nucleotide Polymorphisms (SNPs) of P53 Pro72Arg, MDM2 SNP309, P21 Ser31Arg, ER SNP594, HER2 Ile655Val, and FGFR2 rs2981582 have drawn attention as genetic factors associated with cancer risk.
|
31759353 |
2019 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
TP53 Arg72Pro (rs1042522 C > G) and miR-34b/c rs4938723 (T > C) polymorphisms have been known to modify cancer susceptibility.
|
31325764 |
2019 |
|
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
From other HPV-related malignancies a link between a functional SNP in the p53 gene (rs1042522, p.Arg72Pro) and a higher disease risk in the presence of HPV is documented.
|
30519324 |
2018 |
|
rs1131691014
|
|
|
0.100 |
GeneticVariation |
BEFREE |
From other HPV-related malignancies a link between a functional SNP in the p53 gene (rs1042522, p.Arg72Pro) and a higher disease risk in the presence of HPV is documented.
|
30519324 |
2018 |
|
rs121912664
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, our results suggest that MDM2 SNP 309 may contribute to the LFL phenotype and also to an earlier age at diagnosis of ACC and BC cancer in carriers of the R337H founder mutation.
|
28756477 |
2018 |
|
rs121912664
|
|
|
0.100 |
GeneticVariation |
BEFREE |
By modeling a <i>TP53</i> mutation in mice that has relatively weak cancer penetrance, this study provides <i>in vivo</i> evidence that the human R337H mutation can compromise p53 activity and promote tumorigenesis.<b>Significance:</b> A germline mutation in the oligomerization domain of p53 decreases its transactivation potential and renders mice susceptible to carcinogen-induced liver tumorigenesis.<i>Cancer Res; 78(18); 5375-83.©2018 AACR</i>.
|
30042151 |
2018 |
|
rs121912664
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In southern Brazil, pediatric adrenocortical tumor is a sentinel cancer for detecting families with germline p.R337H mutation in TP53 gene.
|
28864397 |
2018 |
|
rs28934576
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These results indicate that mutant TP53 G245C and R273H can lead to more aggressive phenotypes and enhance cancer cell malignancy, which further uncover TP53 function in carcinogenesis and might be useful in clinical diagnosis and therapy of TP53 mutant cancers.
|
30126368 |
2018 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
From other HPV-related malignancies a link between a functional SNP in the p53 gene (rs1042522, p.Arg72Pro) and a higher disease risk in the presence of HPV is documented.
|
30519324 |
2018 |
|
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Previous studies have indicated that the <i>TP53</i> gene Arg72Pro (rs1042522 C>G) polymorphism is associated with susceptibility to various types of cancer.
|
28275206 |
2017 |
|
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
As ionizing radiation (IR) treatment is often used in cancer therapy, we sought to test the physiological effects of IR in mouse models of the p53 R72P polymorphism.
|
28594296 |
2017 |
|
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Of them, a nonsynonymous polymorphism, Arg72Pro (rs1042522 C>G), has been most extensively studied for the association with cancer risk; however, few studies have investigated its effect on Wilms' tumor.
|
28260929 |
2017 |
|
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Risk of cancer</span> specific mortality, cardiovascular mortality, and respiratory mortality were not associated with Arg72Pro genotype overall; however, in exploratory subgroup analyses, genotype-associated risks of malignant melanoma and diabetes were altered.
|
28336930 |
2017 |
|
rs1131691014
|
|
|
0.100 |
GeneticVariation |
BEFREE |
As ionizing radiation (IR) treatment is often used in cancer therapy, we sought to test the physiological effects of IR in mouse models of the p53 R72P polymorphism.
|
28594296 |
2017 |
|
rs1131691014
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Risk of cancer</span> specific mortality, cardiovascular mortality, and respiratory mortality were not associated with Arg72Pro genotype overall; however, in exploratory subgroup analyses, genotype-associated risks of malignant melanoma and diabetes were altered.
|
28336930 |
2017 |
|
rs1131691014
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Of them, a nonsynonymous polymorphism, Arg72Pro (rs1042522 C>G), has been most extensively studied for the association with cancer risk; however, few studies have investigated its effect on Wilms' tumor.
|
28260929 |
2017 |
|
rs121912664
|
|
|
0.100 |
GeneticVariation |
BEFREE |
TP53 R337H carriers have a lifelong predisposition to cancer with a bimodal age distribution: 1 peak, represented by ACT, occurs in the first decade of life, and another peak of diverse cancer types occurs in the fifth decade.
|
28387921 |
2017 |
|
rs28934576
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Expression of mutp53-R273H also makes cancer cells more sensitive to DNA2 depletion or DNA2 inhibitors.
|
28439015 |
2017 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Of them, a nonsynonymous polymorphism, Arg72Pro (rs1042522 C>G), has been most extensively studied for the association with cancer risk; however, few studies have investigated its effect on Wilms' tumor.
|
28260929 |
2017 |